Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M45.7Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-0.5
Enterprise Value $M-15.9EPS (TTM) $-2.0Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book0.710-y EBITDA Growth Rate %--Quick Ratio9.5Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio9.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-45.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NVLS

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NVLS is held by these investors:



NVLS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rodman David MalcomExec Vice President and CMO 2017-01-04Sell6,687$2.27-3.08view
Carruthers R MichaelExec Vice President / CFO 2016-12-02Buy24,000$2.095.26view
Rodman David MalcomExec Vice President and CMO 2016-10-04Sell5,820$7.96-72.36view
Rodman David MalcomExec Vice President and CMO 2016-07-05Sell5,950$4.66-52.79view
Congleton JonPresident and CEO 2016-06-16Buy5,000$3.87-43.15view
Congleton JonPresident and CEO 2016-03-24Buy5,000$4.22-47.87view
Congleton JonPresident and CEO 2016-03-22Buy5,000$4.38-49.77view
Congleton JonPresident and CEO 2015-12-11Buy5,000$8.1-72.84view
CONWAY ROBERT EDirector 2015-12-09Buy10,000$8.1-72.84view
Flynn James E 2015-06-23Buy250,000$14-84.29view

Quarterly/Annual Reports about NVLS:

News about nvls:

Articles On GuruFocus.com
No related article found.

More From Other Websites
What's in Store for Nivalis (NVLS) this Earnings Season? Apr 26 2017
[$$] Alpine Immune Sciences To Go Public Through Reverse Merger With Nivalis Apr 20 2017
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine Apr 20 2017
Colorado biotech firm is being acquired to create $90M company in Seattle Apr 18 2017
Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger Apr 18 2017
Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to Combine Apr 18 2017
Vertex Pharma Cystic Fibrosis Combo Succeeds (VRTX) Mar 29 2017
Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016... Mar 15 2017
Here’s What Happened With Cyclacel Pharmaceuticals Inc (CYCC) And Nivalis Therapeutics Inc (NVLS) Feb 24 2017
Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor... Feb 23 2017
Nivalis Therapeutics reports 4Q loss Feb 14 2017
Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results Feb 13 2017
BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda Jan 19 2017
Here’s What Happens Now At Nivalis Therapeutics Inc (NVLS) Jan 16 2017
Colorado biotech to streamline operations, explore alternatives after clinical trial failure Jan 04 2017
New Strong Buy Stocks for December 30th Dec 30 2016
These 5 Stocks Under $10 Could Make You a Lot of Money Dec 22 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)